J

Power Law company profile

Juvenescence

Biotech & Life Sciences · Dublin, Ireland · Founded 2016

Juvenescence is a clinical-stage biotechnology company developing medicines aimed at modifying aging and extending the healthy human lifespan. Founded in 2017 by Jim Mellon, Dr. Greg Bailey, and Dr. Declan Doogan, the company operates on a hub-and-spoke model, building a diversified portfolio of assets through investments, joint ventures, and in-licensing compounds. This strategy allows Juvenescence to advance a broad pipeline targeting various mechanisms of aging. The firm has successfully raised approximately $290 million over seven funding rounds to support its initiatives. The founders bring a wealth of relevant experience. Jim Mellon, an author and investor, identified the emerging longevity sector as a significant investment opportunity, even authoring a book titled "Juvenescence: Investing in the Age of Longevity". Dr. Greg Bailey, the Executive Chairman, is a physician and serial biotech entrepreneur with a history of financing and founding successful healthcare companies like Medivation and Biohaven. His journey began in emergency medicine, which provided him with a frontline view of age-related health decline, motivating his shift towards prevention. Dr. Declan Doogan previously served as a senior executive in drug development at Pfizer. Together, the leadership team possesses extensive experience in pharmaceutical R&D, finance, and marketing. Juvenescence's business is structured into several divisions to tackle aging from multiple angles. JuvRx focuses on prescription drug therapies, JuvRegeneration on cell and tissue regeneration, and JuvDataScience leverages artificial intelligence and machine learning to accelerate drug discovery. Its core pipeline includes a PAI-1 inhibitor for fibrosis, a GDF-15 monoclonal antibody, a CD38 inhibitor, and a prescription-strength ketone therapy (Ketone Rx). Beyond pharmaceuticals, the JuvLife division develops intellectual property-protected, non-prescription consumer products, such as supplements and medical foods. One of its first products is Metabolic Switch, a ketone ester drink designed to induce ketosis, developed in partnership with the Buck Institute for Research on Aging. The company's revenue model is based on developing and eventually commercializing these assets, either through direct sales, out-licensing to larger pharmaceutical partners, or company sales. It also generates revenue from its consumer-facing JuvLife products. Juvenescence's unique structure involves investing in a portfolio of external companies that have their own management teams but benefit from a collaborative ecosystem. Notable investments and collaborations include LyGenesis for organ regeneration, Relation Therapeutics for AI-driven drug discovery, Serina Therapeutics for drug delivery technology, and a recent strategic partnership with M42, an Abu Dhabi-based health-tech company, to establish a drug development hub. Keywords: longevity, healthy aging, drug development, biotechnology, life sciences, age-related diseases, cellular regeneration, tissue engineering, artificial intelligence in drug discovery, PAI-1 inhibitor, ketone ester, Metabolic Switch, Jim Mellon, Greg Bailey, JuvLife, JuvRx, healthspan, anti-aging therapies, regenerative medicine, clinical trials